Afuco™ Anti-Human MCAM ADCC Therapeutic Antibody (ABX-MA1), ADCC Enhanced
Anti-MCAM ADCC Enhanced Antibody (ABX-MA1) is an ADCC enhanced antibody produced by our Afuco™ platform. ABX-MA1 is a fully human anti-MUC18 antibody relates to angiogenesis, tumor growth, and metastasis. ABX-MA1 treatment of melanoma cells in vitro significantly inhibited the promoter and collagenase activity of matrix metalloproteinase 2, resulting in decreased invasion through Matrigel-coated filters. ABX-MA1 directly disrupted the tube-like formation by HUVECs in an in vitro vessel formation assay. Collectively, these results point to usefulness of ABX-MA1 as a modality to treat melanoma either alone or in combination with conventional chemotherapy or other antitumor agents.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-496CL |
| Pricing | Inquiry |
| Host | Human |
| Target | MCAM |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided. |